Glofitamab Clinical Trials (2026): 74 Studies for Mantle Cell Lymphoma & Lymphoma
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
74 Glofitamab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 47 indications (including Mantle Cell Lymphoma & Lymphoma) and 7,762 total planned enrollment. 3 Phase 3 Glofitamab trials and 40 Phase 2, 1 Phase 4 are listed. 53 Glofitamab clinical trials are actively recruiting at 169 U.S. sites across 37 states. Most recent activity: NCT05833763 (Apr 2037).
Where to Participate: All Glofitamab Trial Sites in the U.S. (169 sites across 37 states)
Every actively recruiting Glofitamabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | Children's Hospital of Alabama | Birmingham35233 | NCT05533775 | Map |
| AK | Alaska Oncology & Hematology, LLC | Anchorage99508 | NCT06806033 | Map |
| AZ | Mayo Clinic in Arizona - Phoenix | Phoenix85054 | NCT06090539 | Map |
| AZ | Mayo Clinic Phoenix | Phoenix85054-4502 | NCT06634589 | Map |
| CA | Community Cancer Institute (CCI) | Clovis93611 | NCT06806033 | Map |
| CA | University of California San Francisco - Fresno Center for Medical Education and Research | Clovis93611 | NCT04970901 | Map |
| CA | University of California, Davis | Davis95616 | NCT06252675 | Map |
| CA | City of Hope Cancer Center | Duarte91010 | NCT06084936 | Map |
| CA | City of Hope Comprehensive Cancer Center | Duarte91010 | NCT06090539 | Map |
| CA | City of Hope Comprehensive Cancer Center | Duarte91010 | NCT07003295 | Map |
| CA | City of Hope Medical Center | Duarte91010 | NCT05861050 | Map |
| CA | City of Hope Medical Center | Duarte91010 | NCT06054776 | Map |
| CA | City of Hope Medical Center | Duarte91010 | NCT06922604 | Map |
| CA | Providence Medical Foundation | Fullerton92835 | NCT06806033 | Map |
| CA | Los Angeles Cancer Network | Glendale91204 | NCT06806033 | Map |
| CA | UC San Diego Moores Cancer Center | La Jolla92093 | NCT06624085 | Map |
| CA | Saddleback Memorial Medical Center | Laguna Hills92653 | NCT06624085 | Map |
| CA | University of California, Los Angeles | Los Angeles90095 | NCT06252675 | Map |
| CA | University of Southern California Norris Comprehensive | Los Angeles90033 | NCT06634589 | Map |
| CA | Valkyrie Clinical Trials | Los Angeles90067 | NCT06806033 | Map |
| CA | Kaiser Permanente Oakland Medical Center | Oakland94611 | NCT05533775 | Map |
| CA | UCSF Benioff Children's Hospital Oakland | Oakland94609 | NCT05533775 | Map |
| CA | Valkyrie Clinical Trials | Panorama City91402 | NCT06806033 | Map |
| CA | Kaiser Permanente - Roseville | Roseville95661 | NCT05533775 | Map |
| CA | Scripps Health - Prebys Cancer Center | San Diego92103 | NCT04970901 | Map |
| CA | UCSF/Hematology, Blood & Marrow Transplant, And Cellular Therapy (HBC) Program | San Francisco94143 | NCT05169515 | Map |
| CA | University of California, San Francisco | San Francisco94143 | NCT06252675 | Map |
| CA | Zuckerberg San Francisco General Hospital | San Francisco94110 | NCT06806033 | Map |
| CA | Kaiser Permanente - Santa Clara | Santa Clara95051 | NCT05533775 | Map |
| CA | University of California Los Angeles (UCLA) - Cancer Care - Santa Monica | Santa Monica90404-2023 | NCT06084936 | Map |
| CA | University of California Los Angeles (UCLA) - Cancer Care - Santa Monica | Santa Monica90404-2023 | NCT06624085 | Map |
| CA | The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Cente | Torrance90502-2006 | NCT06806033 | Map |
| CO | Rocky Mountain Cancer Centers, LLP | Aurora80012 | NCT06806033 | Map |
| CO | University of Colorado | Aurora80045 | NCT05169515 | Map |
| CT | Clinical Trial Site | New Haven06510 | NCT06393738 | Map |
| CT | Yale Cancer Center | New Haven06520 | NCT06084936 | Map |
| DC | Georgetown University | Washington D.C.20007 | NCT06084936 | Map |
| DC | Georgetown University | Washington D.C.20007 | NCT06624085 | Map |
| FL | University of Miami | Coral Gables33146 | NCT06084936 | Map |
| FL | North Florida/ South Georgia VA Medical Center | Gainesville32608 | NCT06806033 | Map |
| FL | Mayo Clinic Jacksonville | Jacksonville32224-1865 | NCT06634589 | Map |
| FL | Miami Cancer Institute | Miami33176 | NCT04970901 | Map |
| FL | Mount Sinai Comprehensive Cancer Center | Miami33140 | NCT06806033 | Map |
| FL | Sylvester Comprehensive Cancer Center | Miami33136 | NCT04970901 | Map |
| FL | University of Miami Sylvester Cancer Center | Miami33136 | NCT05800366 | Map |
| FL | AdventHealth Cancer Institute | Orlando32804 | NCT06624085 | Map |
| FL | Orlando Health Cancer Institute | Orlando32806 | NCT06806033 | Map |
| FL | Memorial Cancer Institute - Memorial Hospital West | Pembroke Pines33028 | NCT04970901 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT05169515 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT06090539 | Map |
| FL | Moffitt Cancer Center | Tampa33612-9496 | NCT06634589 | Map |
| GA | Emory Saint Joseph's Hospital | Atlanta30342 | NCT07003295 | Map |
| GA | Emory University Hospital Midtown | Atlanta30308 | NCT07003295 | Map |
| GA | Emory University Hospital/Winship Cancer Institute | Atlanta30322 | NCT07003295 | Map |
| GA | The Blood and Marrow Transplant Group of Georgia | Atlanta30342 | NCT04970901 | Map |
| GA | Winship Cancer Institute at Emory University | Atlanta30322 | NCT06043674 | Map |
| GA | Winship Cancer Institute of Emory University | Atlanta30322 | NCT04970901 | Map |
| GA | Winship Cancer Institute of Emory University | Atlanta30329 | NCT06624085 | Map |
| ID | St Luke?s Cancer Institute | Boise83712 | NCT06806033 | Map |
| IL | The University of Chicago | Chicago60637 | NCT05169515 | Map |
| IL | University of Illinois Cancer Center | Chicago60612 | NCT06624085 | Map |
| IL | Cancer Care Specialists of Central Illinois | Swansea62226 | NCT06806033 | Map |
| IA | Mission Cancer + Blood - Mission Cancer Foundation | Des Moines50309 | NCT04970901 | Map |
| IA | Mission Blood and Cancer - MercyOne Cancer Center | Waukee50263 | NCT06806033 | Map |
| KS | Kansas City VA Medical Center | Kansas City64128 | NCT06624085 | Map |
| KS | The University of Kansas Cancer Center | Westwood66205-2003 | NCT06634589 | Map |
| KY | University of Kentucky - Markey Cancer Center | Lexington40536 | NCT06806033 | Map |
| LA | Mary Bird Perkins Cancer Ctr | Baton Rouge70809 | NCT06806033 | Map |
| MD | Johns Hopkins University | Baltimore21231 | NCT05533775 | Map |
| MD | Walter Reed National Military Medical Center | Bethesda20814 | NCT06624085 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT04970901 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT05800366 | Map |
| MA | Boston Medical Center | Boston02118 | NCT06806033 | Map |
| MA | Brigham and Women's Hospital | Boston02215 | NCT06043674 | Map |
| MA | Dana Farber Cancer Institute | Boston02215 | NCT05800366 | Map |
| MA | Dana Farber Cancer Institute | Boston02215 | NCT06043674 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT05533775 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT04970901 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT06090539 | Map |
| MI | University of Michigan Health System | Ann Arbor48109 | NCT06084936 | Map |
| MI | Clinical Trial Site | Detroit48201 | NCT06393738 | Map |
| MI | Corewell Health | Grand Rapids49503 | NCT06806033 | Map |
| MN | University of Minnesota | Minneapolis55455 | NCT04970901 | Map |
| MN | Mayo Clinic in Rochester, Minnesota | Rochester55905 | NCT06090539 | Map |
| MN | Mayo Clinic Rochester | Rochester55905-0001 | NCT06634589 | Map |
| MO | St. Luke's Hospital | Chesterfield63017 | NCT06084936 | Map |
| MO | Childrens Mercy Hosp & Clinics | Kansas City64108 | NCT05533775 | Map |
| MO | Washington University School of Medicine | St Louis63110-1010 | NCT06634589 | Map |
| NE | Nebraska Cancer Specialists | Omaha68130 | NCT06806033 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT04889716 | Map |
| NV | Renown Regional Medical Center | Reno89502 | NCT06084936 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) | Basking Ridge07920 | NCT06765317 | Map |
| NJ | Summit Medical Group | Florham Park07932-1049 | NCT06634589 | Map |
| NJ | Hackensack Meridian Health (Data collection only) | Hackensack07601 | NCT06765317 | Map |
| NJ | Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown07748 | NCT06765317 | Map |
| NJ | Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale07645 | NCT06765317 | Map |
| NJ | Clinical Trial Site | New Brunswick10065 | NCT06393738 | Map |
| NJ | Rutgers Cancer Institute of New Jersey | New Brunswick08901 | NCT06084936 | Map |
| NM | Christus Health - Christus St. Vincent Regional Medical Center | Santa Fe87505 | NCT06624085 | Map |
| NY | New York Oncology Hematology, P.C. | Albany12206 | NCT06806033 | Map |
| NY | Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities) | Commack11725 | NCT06765317 | Map |
| NY | Hematology Oncology Associates of Central New York | East Syracuse13057 | NCT06806033 | Map |
| NY | Memorial Sloan Kettering Westchester (All Protocol Activities) | Harrison10604 | NCT06765317 | Map |
| NY | Clinical Trial Site | New York10016 | NCT06393738 | Map |
| NY | Clinical Trial Site | New York10021 | NCT06393738 | Map |
| NY | Columbia University Irving Medical Center | New York10027 | NCT04970901 | Map |
| NY | Columbia University Medical Center | New York10032 | NCT06634589 | Map |
| NY | Icahn School of Medicine At Mount Sinai | New York10029-6504 | NCT06634589 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT06090539 | Map |
| NY | Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York10065 | NCT06765317 | Map |
| NY | Memorial Sloan Kettering Cancer Center Mskcc | New York10065-6800 | NCT06634589 | Map |
| NY | MSKCC | New York10065 | NCT05533775 | Map |
| NY | Weill Cornell Medical College Newyork Presbyterian Hospital | New York10065-4870 | NCT06634589 | Map |
| NY | University of Rochester | Rochester14642 | NCT06084936 | Map |
| NY | University of Rochester | Rochester14642-0001 | NCT06634589 | Map |
| NY | Memorial Sloan Kettering Nassau (Limited Protocol Activities) | Rockville Centre11553 | NCT06765317 | Map |
| NY | Stony Brook Univ Cancer Ctr | Stony Brook11794 | NCT06624085 | Map |
| NC | The University of North Carolina at Chapel Hill | Chapel Hill27599 | NCT06043674 | Map |
| NC | Levine Cancer Institute | Charlotte28204 | NCT05169515 | Map |
| NC | East Carolina University | Greenville27834 | NCT06624085 | Map |
| OH | Cincinnati Children's Hospital Medical Center | Cincinnati45229 | NCT05533775 | Map |
| OH | Cleveland Clinic Main Campus | Cleveland44195 | NCT04970901 | Map |
| OH | Clinical Trial Site | Cleveland44122 | NCT06393738 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT07003295 | Map |
| OH | The Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT06043674 | Map |
| OR | Oncology Associates of Oregon, P.C | Eugene97401 | NCT06806033 | Map |
| OR | OHSU Knight Cancer Institute | Portland97239 | NCT06357676 | Map |
| OR | Oregon Health and Science University | Portland97239 | NCT04970901 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT06806033 | Map |
| OR | Providence St. Vincent Medical Center | Portland97225 | NCT06806033 | Map |
| PA | Abramson Cancer Center of the University of Pennsylvania | Philadelphia19104 | NCT04889716 | Map |
| PA | Fox Chase Cancer Center | Philadelphia19111-2434 | NCT06634589 | Map |
| PA | Penn Medicine - Perelman Center for Advanced Medicine | Philadelphia19104 | NCT04970901 | Map |
| PA | Thomas Jefferson University | Philadelphia19107 | NCT06624085 | Map |
| PA | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh15232 | NCT07003295 | Map |
| RI | Brown University Health - Rhode Island Hospital | Providence02903 | NCT04970901 | Map |
| TN | Tennessee Oncology | Chattanooga37403 | NCT06806033 | Map |
| TN | Clinical Trial Site | Nashville37203 | NCT06393738 | Map |
| TN | Greco-Hainsworth Tennessee Oncology Centers for Research (GHCR) | Nashville37203 | NCT04970901 | Map |
| TN | Tennessee Oncology | Nashville37203 | NCT06806033 | Map |
| TN | Vanderbilt University/Ingram Cancer Center | Nashville37232 | NCT07003295 | Map |
| TX | Baylor University Medical Center | Dallas75246 | NCT04970901 | Map |
| TX | Renovatio Clinical - El Paso | El Paso79915 | NCT06084936 | Map |
| TX | Renovatio Clinical - El Paso | El Paso79915 | NCT06624085 | Map |
| TX | Baylor College of Medicine | Houston77030 | NCT06624085 | Map |
| TX | Clinical Trial Site | Houston77030 | NCT06393738 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT06213311 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT07257055 | Map |
| TX | The University of Texas Md Anderson Cancer Center | Houston77030-4009 | NCT06634589 | Map |
| TX | UT MD Anderson Cancer Center | Houston77030 | NCT05169515 | Map |
| TX | Baylor Scott & White Health | Temple76502 | NCT06806033 | Map |
| TX | Renovatio Clinical | The Woodlands77380 | NCT06084936 | Map |
| TX | Renovatio Clinical | The Woodlands77380 | NCT06624085 | Map |
| TX | Texas Oncology - Gulf Coast | The Woodlands77380 | NCT06806033 | Map |
| TX | Texas Oncology- Northeast Texas | Tyler75702 | NCT06806033 | Map |
| UT | Huntsman Cancer Institute | Salt Lake City84112 | NCT04970901 | Map |
| UT | Huntsman Cancer Institute | Salt Lake City84112 | NCT05861050 | Map |
| UT | Huntsman Cancer Institute | Salt Lake City84112-5550 | NCT06634589 | Map |
| UT | Huntsman Cancer Institute at University of Utah | Salt Lake City84112 | NCT07528352 | Map |
| VA | Emily Couric Clinical Cancer Center | Charlottesville22903 | NCT04970901 | Map |
| VA | University of Virginia | Charlottesville22906 | NCT06084936 | Map |
| VA | Virginia Cancer Specialists, PC | Fairfax22031 | NCT06806033 | Map |
| VA | Virginia Oncology Associates - Virginia Beach | Virginia Beach23456 | NCT06806033 | Map |
| WA | Fred Hutch/University of Washington Cancer Consortium | Seattle98109 | NCT04231877 | Map |
| WA | Northwest Medical Specialties | Tacoma98405 | NCT06806033 | Map |
| WV | West Virginia University | Morgantown26506 | NCT06084936 | Map |
| WI | University of Wisconsin | Madison53792-0001 | NCT06634589 | Map |
| WI | Froedtert & Medical College of Wisconsin | Milwaukee53226 | NCT04970901 | Map |
| WI | Medical College of Wisconsin | Milwaukee53226-1222 | NCT06634589 | Map |
Glofitamab clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | terminated | withdrawn | not yet recruiting | Total |
|---|---|---|---|---|---|---|---|
| Early P1 | 1 | 1 | |||||
| P1 | 7 | 1 | 4 | 1 | 1 | 14 | |
| P1/P2 | 5 | 4 | 1 | 10 | |||
| P2 | 23 | 6 | 1 | 10 | 40 | ||
| P3 | 1 | 2 | 3 | ||||
| P4 | 1 | 1 | |||||
| N/A | 4 | 1 | 5 |
Recruiting Glofitamab clinical trials (53)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT05833763 | GOlDiLOXA Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure. | P2 | Mantle Cell Lymphoma | 42 | Oct 2023 |
| NCT06043674 | Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation | P2 | Chronic Lymphocytic Leukemia | 70 | Jan 2024 |
| NCT05533775 | iMATRIX GLOA Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma | P1/P2 | Mature B-Cell Non-Hodgkin Lymphoma | 65 | Nov 2022 |
| NCT06558604 | GLOASISPhase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma | P2 | Lymphoma, Mantle-Cell | 100 | Feb 2025 |
| NCT07387848 | GLO-PACTGlofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas | P2 | Diffuse Large B Cell Lymphoma Refractory | 40 | Apr 2026 |
| NCT04231877 | Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma | P1 | Aggressive Non-Hodgkin Lymphoma | 56 | Oct 2020 |
| NCT07184788 | G-Pola-GemOx in Refractory/Relapsed Aggressive B-Cell Lymphoma | P2 | Aggressive B-Cell Lymphoma | 80 | Oct 2025 |
| NCT07528352 | REBELExternal Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL | P1 | Diffuse Large B Cell Lymphoma | 12 | Jun 2026 |
| NCT07257055 | Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study | P2 | Phase 2 Study | 30 | Apr 2026 |
| NCT07453095 | Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy | P2 | Mantle Cell Lymphoma | 41 | Apr 2026 |
| NCT06624085 | A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | P1 | Lymphoma | 50 | Apr 2025 |
| NCT06665217 | G-Pola-ZLP in Diffuse Large B-Cell Lymphoma | P2 | Diffuse Large B-Cell Lymphoma | 80 | Sep 2025 |
| NCT07514169 | SILVERGLOThe Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL | P2 | Large B-Cell Lymphoma (LBCL) | 30 | Mar 2026 |
| NCT07460362 | Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma | P2 | MCL | 43 | Aug 2025 |
| NCT06634589 | A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies | P1/P2 | B-cell Malignancy | 80 | Nov 2024 |
| NCT07502872 | TPGTPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma | P2 | Diffuse Large B Cell Lymphoma | 30 | May 2026 |
| NCT06357676 | Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial | P1/P2 | Mantle Cell Lymphoma | 27 | May 2025 |
| NCT07200375 | GlofitRealAn Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma | — | Diffuse Large B-Cell Lymphoma | 300 | Sep 2025 |
| NCT05800366 | A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma | P2 | Lymphoma | 41 | Apr 2023 |
| NCT05169515 | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma | P1 | Non-Hodgkin Lymphoma | 121 | Oct 2022 |
| NCT07326371 | Glofitamab Combined With CAR-T Therapy in R/R DLBCL | P2 | DLBCL - Diffuse Large B Cell Lymphoma | 24 | Mar 2026 |
| NCT06806033 | A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma | P2 | B-Cell Non-Hodgkins Lymphoma | 100 | Mar 2025 |
| NCT06922604 | Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma | P1 | Primary Central Nervous System Lymphoma | 20 | Jul 2025 |
| NCT06956092 | GlofitamabGlofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma | P4 | B Cell Lymphoma (BCL) | 40 | May 2025 |
| NCT06570447 | Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL | P2 | Diffuse Large B-Cell Lymphoma-Recurrent | 22 | May 2025 |
| NCT06481826 | Glofitamab in Chinese Patients With R/R DLBCL | — | DLBCL - Diffuse Large B Cell Lymphoma | 20 | Jan 2024 |
| NCT04889716 | CAR-T Followed by Bispecific Antibodies | P2 | Large B-cell Lymphoma | 23 | Nov 2021 |
| NCT07240194 | LBCLThe Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study | P2 | Large B-cell Lymphoma | 24 | Sep 2025 |
| NCT06090539 | A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas | P1/P2 | Relapsed/Refractory Non-Hodgkin Lymphoma | 308 | Dec 2023 |
| NCT07231250 | Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma | P2 | DLBCL - Diffuse Large B Cell Lymphoma | 40 | Jan 2026 |
| NCT06656234 | The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study | — | Diffuse Large B Cell Lymphoma (DLBCL) | 200 | Oct 2024 |
| NCT06867536 | GLOHRT-01Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden | P2 | Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | 40 | Apr 2025 |
| NCT06252675 | Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma | P2 | Mantle Cell Lymphoma | 30 | Jun 2024 |
| NCT06651853 | Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL | P2 | Diffuse Large B-cell Lymphoma | 22 | Oct 2024 |
| NCT06071871 | PORTALA Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma | P2 | Large B-cell Lymphoma | 99 | Aug 2024 |
| NCT06656221 | A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma | P2 | Mantle Cell Lymphoma | 29 | Dec 2024 |
| NCT06393738 | A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. | P1 | Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) | 255 | Sep 2024 |
| NCT06084936 | GLOBRYTEA Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma | P3 | Lymphoma | 182 | Oct 2023 |
| NCT06765317 | A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma | P2 | Diffuse Large B Cell Lymphoma (DLBCL) | 42 | Jan 2025 |
| NCT06996132 | Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma | P2 | Relapsed or Refractory Aggressive B-cell Lymphoma | 25 | May 2025 |
| NCT06050694 | GRAILFeasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL) | P2 | Diffuse Large B Cell Lymphoma (DLBCL) | 40 | Jan 2025 |
| NCT04970901 | LOTIS-7A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) | P1 | B-Cell Non-Hodgkin Lymphoma | 200 | Jun 2022 |
| NCT06567366 | CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors | P2 | Large B-cell Lymphoma | 45 | Sep 2024 |
| NCT07444710 | Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma | P1 | Ann Arbor Stage II Mantle Cell Lymphoma | 16 | Aug 2026 |
| NCT07003295 | Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy | P2 | Recurrent Mantle Cell Lymphoma | 20 | Aug 2026 |
| NCT06186648 | GLORIFYEvaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome | P2 | Richter Syndrome | 40 | Mar 2024 |
| NCT05861050 | Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma | P1/P2 | Blastoid Variant Mantle Cell Lymphoma | 50 | Aug 2023 |
| NCT06213311 | A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma | P2 | B Cell Lymphoma | 40 | May 2024 |
| NCT06534437 | JASPIS-01MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01) | P2 | Non-Hodgkin Lymphoma, B-cell | 178 | Dec 2024 |
| NCT06994169 | Glofitamab in Real Life | — | Large B-cell Lymphoma | 250 | Dec 2025 |
| NCT06054776 | Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | P2 | Mantle Cell Lymphoma | 40 | Dec 2024 |
| NCT07012980 | Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL | P2 | Diffuse Large B-Cell Lymphoma | 38 | Jun 2025 |
| NCT06497452 | GLOFTSTA Study of Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Chinese Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. | — | B-cell Non-Hodgkin Lymphoma | 50 | Jun 2024 |
Glofitamab clinical trials by indication
Mantle Cell Lymphoma (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05833763 | GOlDiLOX | P2 | recruiting | A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure. |
| NCT07453095 | — | P2 | not yet recruiting | Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy |
| NCT06357676 | — | P1/P2 | recruiting | Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial |
| NCT06252675 | — | P2 | recruiting | Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma |
| NCT06656221 | — | P2 | not yet recruiting | A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma |
| NCT06192888 | — | P1 | active not recruiting | A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma |
| NCT06054776 | — | P2 | recruiting | Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma |
Large B-cell Lymphoma (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04889716 | — | P2 | recruiting | CAR-T Followed by Bispecific Antibodies |
| NCT07240194 | LBCL | P2 | recruiting | The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study |
| NCT06071871 | PORTAL | P2 | recruiting | A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma |
| NCT06567366 | — | P2 | not yet recruiting | CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors |
| NCT06994169 | — | N/A | recruiting | Glofitamab in Real Life |
Lymphoma (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06624085 | — | P1 | recruiting | A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
| NCT05800366 | — | P2 | recruiting | A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma |
| NCT06084936 | GLOBRYTE | P3 | recruiting | A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma |
| NCT04980222 | R | P2 | active not recruiting | A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma |
| NCT04657302 | — | P1 | completed | A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
Diffuse Large B Cell Lymphoma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07528352 | REBEL | P1 | recruiting | External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL |
| NCT07502872 | TPG | P2 | not yet recruiting | TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma |
| NCT06552572 | Glory | P2 | active not recruiting | Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy |
| NCT04914741 | COALITION | P1/P2 | active not recruiting | A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL) |
Diffuse Large B-Cell Lymphoma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06665217 | — | P2 | not yet recruiting | G-Pola-ZLP in Diffuse Large B-Cell Lymphoma |
| NCT07200375 | GlofitReal | N/A | recruiting | An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma |
| NCT07012980 | — | P2 | not yet recruiting | Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL |
| NCT05896163 | MAPtivate-6 | P1/P2 | terminated | A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma. |
DLBCL - Diffuse Large B Cell Lymphoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07326371 | — | P2 | not yet recruiting | Glofitamab Combined With CAR-T Therapy in R/R DLBCL |
| NCT06481826 | — | N/A | recruiting | Glofitamab in Chinese Patients With R/R DLBCL |
| NCT07231250 | — | P2 | not yet recruiting | Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma |
Diffuse Large B Cell Lymphoma (DLBCL) (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06656234 | — | N/A | not yet recruiting | The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study |
| NCT06765317 | — | P2 | recruiting | A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma |
| NCT06050694 | GRAIL | P2 | recruiting | Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL) |
B-cell Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06670105 | — | P2 | withdrawn | A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma |
| NCT04313608 | — | P1 | completed | A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma |
Diffuse Large B-cell Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06651853 | — | P2 | recruiting | Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL |
| NCT04408638 | — | P3 | active not recruiting | A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
Lymphoma, Non-Hodgkin (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04077723 | — | P1/P2 | active not recruiting | A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma |
| NCT05219513 | — | P1 | terminated | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma |
Ann Arbor Stage II Mantle Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07444710 | — | P1 | not yet recruiting | Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma |
Recurrent Mantle Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07003295 | — | P2 | recruiting | Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy |
Diffuse Large B Cell Lymphoma Refractory (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07387848 | GLO-PACT | P2 | not yet recruiting | Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas |
Phase 2 Study (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07257055 | — | P2 | recruiting | Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study |
Large B-Cell Lymphoma (LBCL) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07514169 | SILVERGLO | P2 | recruiting | The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL |
Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07480850 | — | P2 | active not recruiting | Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma |
Aggressive B-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07184788 | — | P2 | not yet recruiting | G-Pola-GemOx in Refractory/Relapsed Aggressive B-Cell Lymphoma |
MCL (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07460362 | — | P2 | recruiting | Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma |
Primary Central Nervous System Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06922604 | — | P1 | recruiting | Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma |
B Cell Lymphoma (BCL) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06956092 | Glofitamab | P4 | not yet recruiting | Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma |
Diffuse Large B-Cell Lymphoma-Recurrent (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06570447 | — | P2 | recruiting | Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL |
Relapsed or Refractory Aggressive B-cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06996132 | — | P2 | recruiting | Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma |
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06867536 | GLOHRT-01 | P2 | recruiting | Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden |
B-Cell Non-Hodgkins Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06806033 | — | P2 | recruiting | A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma |
Lymphoma, Mantle-Cell (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06558604 | GLOASIS | P2 | recruiting | Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma |
Non-Hodgkin Lymphoma, B-cell (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06534437 | JASPIS-01 | P2 | recruiting | MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01) |
B-cell Malignancy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06634589 | — | P1/P2 | recruiting | A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies |
Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06393738 | — | P1 | recruiting | A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. |
B-cell Non-Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06497452 | GLOFTST | N/A | recruiting | A Study of Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Chinese Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. |
B Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06213311 | — | P2 | recruiting | A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma |
Richter Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06186648 | GLORIFY | P2 | recruiting | Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome |
Chronic Lymphocytic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06043674 | — | P2 | recruiting | Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation |
Relapsed/Refractory Non-Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06090539 | — | P1/P2 | recruiting | A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas |
Large B-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06047080 | — | P3 | active not recruiting | An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma |
Blastoid Variant Mantle Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05861050 | — | P1/P2 | recruiting | Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma |
Follicular Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05783596 | — | P2 | active not recruiting | Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma |
Lymphoma, Large B-Cell, Diffuse (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05798156 | R-Pola-Glo | P2 | active not recruiting | Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP |
Mature B-Cell Non-Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05533775 | iMATRIX GLO | P1/P2 | recruiting | A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma |
Diffuse Large B-Cell Lymphoma (DLBCL) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05364424 | — | P1 | completed | A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma |
Non-Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05169515 | — | P1 | recruiting | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma |
B-Cell Non-Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04970901 | LOTIS-7 | P1 | recruiting | A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) |
Relapsed/refractory Diffuse Large B Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05335018 | — | P2 | active not recruiting | GPL in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma |
Aggressive Non-Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04231877 | — | P1 | recruiting | Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma |
Lymphoma, B-Cell (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04161248 | — | Early P1 | active not recruiting | Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma |
Non-Hodgkins Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03533283 | — | P1/P2 | active not recruiting | An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma |
B-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03467373 | CHOP | P1 | completed | A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL |
Non-Hodgkin's Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03075696 | RO7082859 | P1/P2 | active not recruiting | A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma |
Glofitamab pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| Glofitamab | NCT06956092 | P4 | not yet recruiting | B Cell Lymphoma (BCL) | 40 | — |
| GLOBRYTE | NCT06084936 | P3 | recruiting | Lymphoma | 182 | — |
| GOlDiLOX | NCT05833763 | P2 | recruiting | Mantle Cell Lymphoma | 42 | — |
| GLOASIS | NCT06558604 | P2 | recruiting | Lymphoma, Mantle-Cell | 100 | — |
| GLO-PACT | NCT07387848 | P2 | not yet recruiting | Diffuse Large B Cell Lymphoma Refractory | 40 | — |
| SILVERGLO | NCT07514169 | P2 | recruiting | Large B-Cell Lymphoma (LBCL) | 30 | — |
| TPG | NCT07502872 | P2 | not yet recruiting | Diffuse Large B Cell Lymphoma | 30 | — |
| LBCL | NCT07240194 | P2 | recruiting | Large B-cell Lymphoma | 24 | — |
| Glory | NCT06552572 | P2 | active not recruiting | Diffuse Large B Cell Lymphoma | 30 | — |
| GLOHRT-01 | NCT06867536 | P2 | recruiting | Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | 40 | — |
| PORTAL | NCT06071871 | P2 | recruiting | Large B-cell Lymphoma | 99 | — |
| R-Pola-Glo | NCT05798156 | P2 | active not recruiting | Lymphoma, Large B-Cell, Diffuse | 125 | — |
| GRAIL | NCT06050694 | P2 | recruiting | Diffuse Large B Cell Lymphoma (DLBCL) | 40 | — |
| GLORIFY | NCT06186648 | P2 | recruiting | Richter Syndrome | 40 | — |
| JASPIS-01 | NCT06534437 | P2 | recruiting | Non-Hodgkin Lymphoma, B-cell | 178 | — |
| R | NCT04980222 | P2 | active not recruiting | Lymphoma | 46 | — |
Terminated and withdrawn Glofitamab trials (3)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT06670105withdrawnA Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma
- NCT05896163terminatedA Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.
- NCT05219513terminatedA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
All Glofitamab trials (74)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT05833763 | GOlDiLOX | A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure. | P2 | recruiting | 42 | Australasian Leukaemia and Lymphoma Group | Oct 2023 |
| NCT06043674 | Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation | P2 | recruiting | 70 | Christine Ryan | Jan 2024 | |
| NCT05533775 | iMATRIX GLO | A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma | P1/P2 | recruiting | 65 | Hoffmann-La Roche | Nov 2022 |
| NCT06558604 | GLOASIS | Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma | P2 | recruiting | 100 | The Lymphoma Academic Research Organisation | Feb 2025 |
| NCT06670105 | A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma | P2 | withdrawn | 0 | M.D. Anderson Cancer Center | Jun 2025 | |
| NCT07387848 | GLO-PACT | Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas | P2 | not yet recruiting | 40 | American University of Beirut Medical Center | Apr 2026 |
| NCT04231877 | Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma | P1 | recruiting | 56 | University of Washington | Oct 2020 | |
| NCT07184788 | G-Pola-GemOx in Refractory/Relapsed Aggressive B-Cell Lymphoma | P2 | not yet recruiting | 80 | Navy General Hospital, Beijing | Oct 2025 | |
| NCT07528352 | REBEL | External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL | P1 | recruiting | 12 | University of Utah | Jun 2026 |
| NCT07257055 | Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study | P2 | recruiting | 30 | M.D. Anderson Cancer Center | Apr 2026 | |
| NCT06047080 | An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma | P3 | active not recruiting | 1,130 | Hoffmann-La Roche | Sep 2023 | |
| NCT07453095 | Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy | P2 | not yet recruiting | 41 | Fondazione Italiana Linfomi - ETS | Apr 2026 | |
| NCT06624085 | A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | P1 | recruiting | 50 | Hoffmann-La Roche | Apr 2025 | |
| NCT06665217 | G-Pola-ZLP in Diffuse Large B-Cell Lymphoma | P2 | not yet recruiting | 80 | Navy General Hospital, Beijing | Sep 2025 | |
| NCT07514169 | SILVERGLO | The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL | P2 | recruiting | 30 | Ruijin Hospital | Mar 2026 |
| NCT07460362 | Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma | P2 | recruiting | 43 | Peking University Third Hospital | Aug 2025 | |
| NCT06634589 | A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies | P1/P2 | recruiting | 80 | BeOne Medicines | Nov 2024 | |
| NCT07502872 | TPG | TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma | P2 | not yet recruiting | 30 | Brown University | May 2026 |
| NCT06357676 | Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial | P1/P2 | recruiting | 27 | OHSU Knight Cancer Institute | May 2025 | |
| NCT07200375 | GlofitReal | An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma | — | recruiting | 300 | Hoffmann-La Roche | Sep 2025 |
| NCT05800366 | A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma | P2 | recruiting | 41 | Jennifer Crombie, MD | Apr 2023 | |
| NCT05169515 | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma | P1 | recruiting | 121 | Hoffmann-La Roche | Oct 2022 | |
| NCT05783596 | Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma | P2 | active not recruiting | 47 | Reid Merryman, MD | Jul 2023 | |
| NCT07326371 | Glofitamab Combined With CAR-T Therapy in R/R DLBCL | P2 | not yet recruiting | 24 | Ruijin Hospital | Mar 2026 | |
| NCT06806033 | A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma | P2 | recruiting | 100 | Hoffmann-La Roche | Mar 2025 | |
| NCT03075696 | RO7082859 | A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma | P1/P2 | active not recruiting | 940 | Hoffmann-La Roche | Feb 2017 |
| NCT06922604 | Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma | P1 | recruiting | 20 | City of Hope Medical Center | Jul 2025 | |
| NCT06956092 | Glofitamab | Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma | P4 | not yet recruiting | 40 | Zhengzhou University | May 2025 |
| NCT06570447 | Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL | P2 | recruiting | 22 | Tianjin Medical University Cancer Institute and Hospital | May 2025 | |
| NCT06481826 | Glofitamab in Chinese Patients With R/R DLBCL | — | recruiting | 20 | Peking Union Medical College Hospital | Jan 2024 | |
| NCT04889716 | CAR-T Followed by Bispecific Antibodies | P2 | recruiting | 23 | Abramson Cancer Center at Penn Medicine | Nov 2021 | |
| NCT07240194 | LBCL | The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study | P2 | recruiting | 24 | The First Affiliated Hospital with Nanjing Medical University | Sep 2025 |
| NCT06552572 | Glory | Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy | P2 | active not recruiting | 30 | Samsung Medical Center | Nov 2024 |
| NCT06090539 | A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas | P1/P2 | recruiting | 308 | Bristol-Myers Squibb | Dec 2023 | |
| NCT07231250 | Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma | P2 | not yet recruiting | 40 | Li Zhiming | Jan 2026 | |
| NCT06656234 | The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study | — | not yet recruiting | 200 | Ruijin Hospital | Oct 2024 | |
| NCT06867536 | GLOHRT-01 | Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden | P2 | recruiting | 40 | Liling Zhang | Apr 2025 |
| NCT06252675 | Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma | P2 | recruiting | 30 | University of California, San Francisco | Jun 2024 | |
| NCT06651853 | Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL | P2 | recruiting | 22 | The First Affiliated Hospital of Xiamen University | Oct 2024 | |
| NCT06071871 | PORTAL | A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma | P2 | recruiting | 99 | University College, London | Aug 2024 |
| NCT06656221 | A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma | P2 | not yet recruiting | 29 | Ruijin Hospital | Dec 2024 | |
| NCT06393738 | A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. | P1 | recruiting | 255 | Arvinas Inc. | Sep 2024 | |
| NCT06084936 | GLOBRYTE | A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma | P3 | recruiting | 182 | Hoffmann-La Roche | Oct 2023 |
| NCT04408638 | A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | P3 | active not recruiting | 270 | Hoffmann-La Roche | Feb 2021 | |
| NCT05798156 | R-Pola-Glo | Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP | P2 | active not recruiting | 125 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Mar 2023 |
| NCT06765317 | A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma | P2 | recruiting | 42 | Memorial Sloan Kettering Cancer Center | Jan 2025 | |
| NCT06192888 | A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma | P1 | active not recruiting | 39 | Memorial Sloan Kettering Cancer Center | Jan 2024 | |
| NCT07480850 | Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma | P2 | active not recruiting | 40 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Jan 2026 | |
| NCT06996132 | Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma | P2 | recruiting | 25 | Institute of Hematology & Blood Diseases Hospital, China | May 2025 | |
| NCT06050694 | GRAIL | Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL) | P2 | recruiting | 40 | University Health Network, Toronto | Jan 2025 |
| NCT04970901 | LOTIS-7 | A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) | P1 | recruiting | 200 | ADC Therapeutics S.A. | Jun 2022 |
| NCT06567366 | CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors | P2 | not yet recruiting | 45 | Ruijin Hospital | Sep 2024 | |
| NCT07444710 | Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma | P1 | not yet recruiting | 16 | National Cancer Institute (NCI) | Aug 2026 | |
| NCT07003295 | Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy | P2 | recruiting | 20 | National Cancer Institute (NCI) | Aug 2026 | |
| NCT04077723 | A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | P1/P2 | active not recruiting | 498 | Hoffmann-La Roche | Aug 2019 | |
| NCT06186648 | GLORIFY | Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome | P2 | recruiting | 40 | French Innovative Leukemia Organisation | Mar 2024 |
| NCT05861050 | Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma | P1/P2 | recruiting | 50 | City of Hope Medical Center | Aug 2023 | |
| NCT06213311 | A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma | P2 | recruiting | 40 | M.D. Anderson Cancer Center | May 2024 | |
| NCT06534437 | JASPIS-01 | MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01) | P2 | recruiting | 178 | Ryvu Therapeutics SA | Dec 2024 |
| NCT04161248 | Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma | Early P1 | active not recruiting | 40 | Canadian Cancer Trials Group | Sep 2020 | |
| NCT06994169 | Glofitamab in Real Life | — | recruiting | 250 | The Lymphoma Academic Research Organisation | Dec 2025 | |
| NCT05335018 | GPL in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma | P2 | active not recruiting | 76 | Seoul National University Hospital | May 2022 | |
| NCT06054776 | Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | P2 | recruiting | 40 | City of Hope Medical Center | Dec 2024 | |
| NCT03533283 | An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | P1/P2 | active not recruiting | 211 | Hoffmann-La Roche | May 2018 | |
| NCT04980222 | R | A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma | P2 | active not recruiting | 46 | Hoffmann-La Roche | Mar 2022 |
| NCT07012980 | Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL | P2 | not yet recruiting | 38 | Shanghai Zhongshan Hospital | Jun 2025 | |
| NCT06497452 | GLOFTST | A Study of Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Chinese Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. | — | recruiting | 50 | The First Affiliated Hospital of Soochow University | Jun 2024 |
| NCT05896163 | MAPtivate-6 | A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma. | P1/P2 | terminated | 40 | Pfizer | Aug 2023 |
| NCT05364424 | A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma | P1 | completed | 43 | Hoffmann-La Roche | Nov 2022 | |
| NCT04914741 | COALITION | A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL) | P1/P2 | active not recruiting | 80 | Peter MacCallum Cancer Centre, Australia | Jun 2021 |
| NCT03467373 | CHOP | A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL | P1 | completed | 111 | Hoffmann-La Roche | Mar 2018 |
| NCT05219513 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | P1 | terminated | 53 | Hoffmann-La Roche | Feb 2022 | |
| NCT04657302 | A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | P1 | completed | 30 | Hoffmann-La Roche | Jan 2021 | |
| NCT04313608 | A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma | P1 | completed | 23 | Hoffmann-La Roche | Jun 2020 |
Glofitamab clinical trials: frequently asked questions
- How many Glofitamab clinical trials are there?
- 74 Glofitamab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 40 are actively recruiting participants. 4 are marked completed.
- Are Glofitamab clinical trials recruiting in 2026?
- Yes — 40 Glofitamab trials are actively recruiting in 2026, with 169 U.S. sites across 37 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Glofitamab being studied for?
- Glofitamab is being studied for Mantle Cell Lymphoma, Lymphoma, Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma, Diffuse Large B Cell Lymphoma and 75 more. The trials are grouped by indication on this page.
- What phase is Glofitamab in?
- Glofitamab clinical trials span 1 Phase 4, 3 Phase 3, 40 Phase 2, 14 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Glofitamab clinical trials?
- The lead sponsor across the most Glofitamab trials is Hoffmann-La Roche, with 45 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Glofitamabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: